Valuation Update With 7 Day Price Move • Apr 06
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹616, the stock trades at a trailing P/E ratio of 12.7x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 27% over the past three years. Reported Earnings • Jan 31
Third quarter 2026 earnings released: EPS: ₹3.60 (vs ₹5.96 in 3Q 2025) Third quarter 2026 results: EPS: ₹3.60 (down from ₹5.96 in 3Q 2025). Revenue: ₹3.85b (up 7.6% from 3Q 2025). Net income: ₹104.9m (down 40% from 3Q 2025). Profit margin: 2.7% (down from 4.9% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. New Risk • Oct 07
New minor risk - Dividend sustainability The dividend is not well covered by earnings. Payout ratio: 0% Dividend yield: 0.3% This is considered a minor risk. Companies that pay out too much of their earnings are at risk of having to reduce or cut their dividend in future. If earnings growth slows or earnings fall, then there may not be enough earnings to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. However, this risk is mitigated by the fact the dividend is covered by cash flows. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Reported Earnings • Jul 17
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: EPS: ₹48.38 (up from ₹34.49 in FY 2024). Revenue: ₹20.0b (up 1.7% from FY 2024). Net income: ₹1.42b (up 39% from FY 2024). Profit margin: 7.1% (up from 5.2% in FY 2024). Revenue missed analyst estimates by 3.1%. Earnings per share (EPS) exceeded analyst estimates by 4.3%. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 15% per year. 공시 • Jun 26
Insecticides (India) Limited to Report Q1, 2026 Results on Aug 13, 2025 Insecticides (India) Limited announced that they will report Q1, 2026 results on Aug 13, 2025 공시 • May 29
Insecticides (India) Limited, Annual General Meeting, Aug 12, 2025 Insecticides (India) Limited, Annual General Meeting, Aug 12, 2025, at 15:00 Indian Standard Time. Reported Earnings • May 29
Full year 2025 earnings released: EPS: ₹48.38 (vs ₹34.59 in FY 2024) Full year 2025 results: EPS: ₹48.38 (up from ₹34.59 in FY 2024). Revenue: ₹20.1b (up 2.1% from FY 2024). Net income: ₹1.42b (up 39% from FY 2024). Profit margin: 7.1% (up from 5.2% in FY 2024). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Apr 22
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹744, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 29x in the Chemicals industry in India. Total returns to shareholders of 58% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹1,012 per share. Reported Earnings • Feb 11
Third quarter 2025 earnings released: EPS: ₹5.96 (vs ₹4.16 in 3Q 2024) Third quarter 2025 results: EPS: ₹5.96 (up from ₹4.16 in 3Q 2024). Revenue: ₹3.58b (flat on 3Q 2024). Net income: ₹173.7m (up 41% from 3Q 2024). Profit margin: 4.9% (up from 3.4% in 3Q 2024). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 8% per year. 공시 • Jan 07
Insecticides (India) Limited Launches New Revolutionary Insecticide, Centran Insecticides (India) Limited has launched, a new revolutionary Insecticide, Centran. This will be a pioneering solution for tackling stem borers in paddy. With its dual-action formula, Centran effectively controls stem bores and help the farmers to achieve healthier crops and better productivity. Paddy is the backbone of the Indian farmers. Stem borers pose a significant threat to their hard work. To address this, new age insecticide Centran has been developed by the R&D Team of Insecticides (India) Limited. Centran is a unique blend of dual active ingredients for pest control and crop nourishment. The product supports robust root development, improves tiller growth, and delivers superior yields, ensuring a higher return on investment for growers. With a strong distribution network and a legacy of empowering agriculture, IIL continues to bring impactful innovations that resonate with the needs of those who grow the nation's food. 공시 • Nov 25
Patent Office, Government of India Grants Patent for an Invention to Insecticides (India) Limited Entitled FUNGICIDAL COMPOSITIONS AND METHODS RELATED THERETO Insecticides (India) Limited announced that the Patent Office, Government of India has granted the Patent for an invention to Insecticides (India) Limited entitled FUNGICIDAL COMPOSITIONS AND METHODS RELATED THERETO for the term of 20 years from 28 June 2019 (Date of Filing). Price Target Changed • Nov 19
Price target decreased by 18% to ₹917 Down from ₹1,124, the current price target is an average from 2 analysts. New target price is 30% above last closing price of ₹708. Stock is up 27% over the past year. The company is forecast to post earnings per share of ₹47.06 for next year compared to ₹34.59 last year. Reported Earnings • Nov 15
Second quarter 2025 earnings released: EPS: ₹20.78 (vs ₹17.95 in 2Q 2024) Second quarter 2025 results: EPS: ₹20.78 (up from ₹17.95 in 2Q 2024). Revenue: ₹6.27b (down 9.9% from 2Q 2024). Net income: ₹614.9m (up 16% from 2Q 2024). Profit margin: 9.8% (up from 7.6% in 2Q 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Nov 14
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to ₹729, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 68% over the past three years. 공시 • Oct 04
Insecticides (India) Limited Launches Torry Super with SPF Technology Insecticides (India) Limited has launched Torry Super, a revolutionary post emergence herbicide designed to redefine weed control while ensuring crop safety. IIL continues to bring the latest technology with its latest post emergence herbicide Torry Super, leveraging SPF Technology to deliver unparalleled efficacy. Key benefits of Torry Super include faster weed control, visible results within 3-5 days of application, powerful weed control with extended residual activity for up to 15 days beyond conventional herbicides. Its unique SPF Technology enhances crop tolerance to herbicidal effects, ensuring robust plant health throughout the growing season. Ease of application is another key benefit of Torry Super. Date of Launch: October 5, 2024. 공시 • Aug 30
Insecticides (India) Limited (BSE:532851) announces an Equity Buyback for 500,000 shares, representing 1.69% for INR 500 million. Insecticides (India) Limited (BSE:532851) announces a share repurchase program. Under the program, the company will repurchase up to 500,000 shares, representing 1.69% of its issued share capital for a total of INR 500 million. The share will be repurchased at a price not exceeding INR 1,000 per share. The company announced that it has fixed September 11, 2024, as record date for the offer. As of August 30, 2024, the company has 29,597,837 shares in issue. Upcoming Dividend • Aug 16
Upcoming dividend of ₹2.00 per share Eligible shareholders must have bought the stock before 23 August 2024. Payment date: 08 September 2024. Payout ratio is a comfortable 8.7% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (0.7%). Price Target Changed • Aug 13
Price target increased by 33% to ₹862 Up from ₹646, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of ₹873. Stock is up 89% over the past year. The company is forecast to post earnings per share of ₹38.40 for next year compared to ₹34.59 last year. 공시 • Aug 09
Insecticides (India) Limited Declares Interim Dividend for the Financial Year 2024-2025, Payable on or from August 28, 2024 Insecticides (India) Limited announced that at the Board of Directors of the Company at their meeting held August 9, 2024, declared an Interim Dividend of INR 2.00 per equity shares [20%] of face value of INR 10 each for financial year 2024-2025. The record date as informed for the purpose of determining for entitlement of the shareholders for the payment of Interim Dividend is 23 August, 2024 and the Interim Dividend will be paid to the shareholders, subject to deduction/withholding of applicable taxes, within the time prescribed under law. The Interim Dividend will be paid on or from August 28, 2024. Reported Earnings • Jul 23
Full year 2024 earnings released: EPS: ₹34.59 (vs ₹21.36 in FY 2023) Full year 2024 results: EPS: ₹34.59 (up from ₹21.36 in FY 2023). Revenue: ₹19.7b (up 9.2% from FY 2023). Net income: ₹1.02b (up 62% from FY 2023). Profit margin: 5.2% (up from 3.5% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings. 공시 • Jul 15
Insecticides (India) Limited Announces Resignation of P. C. Pabbi, Sr. VP Commercial Insecticides (India) Limited announced resignation of P. C. Pabbi, Sr. VP Commercial. Mr. P. C. Pabbi, Sr. VP Commercial, who has attained the age of 60 years on March 22, 2021 and further on extension, superannuated and relieved from his services July 15, 2024. Valuation Update With 7 Day Price Move • Jun 11
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹609, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 30% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹418 per share. 공시 • May 31
Insecticides (India) Limited, Annual General Meeting, Aug 12, 2024 Insecticides (India) Limited, Annual General Meeting, Aug 12, 2024, at 15:00 Indian Standard Time. 공시 • May 30
Insecticides (India) Limited Announces Directorate Changes Insecticides (India) Limited announced that The Board took note of the retirement of Mr. Virjesh Kumar Gupta and Mr. Navin Shah, which will take effect on May 30, 2024, marking the completion of theirsecond term. Mr. Virjesh Kumar Gupta and Mr. Navin Shah have served as independent directors for consecutive two terms, with the present term spanning five years from May 31, 2019, to May 30, 2024. Reported Earnings • May 29
Full year 2024 earnings released: EPS: ₹34.59 (vs ₹21.36 in FY 2023) Full year 2024 results: EPS: ₹34.59 (up from ₹21.36 in FY 2023). Revenue: ₹19.8b (up 9.7% from FY 2023). Net income: ₹1.02b (up 62% from FY 2023). Profit margin: 5.2% (up from 3.5% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Price Target Changed • Feb 29
Price target increased by 12% to ₹646 Up from ₹575, the current price target is an average from 3 analysts. New target price is 20% above last closing price of ₹537. Stock is up 27% over the past year. The company is forecast to post earnings per share of ₹33.50 for next year compared to ₹21.36 last year. Reported Earnings • Feb 06
Third quarter 2024 earnings released: EPS: ₹4.16 (vs ₹3.16 in 3Q 2023) Third quarter 2024 results: EPS: ₹4.16 (up from ₹3.16 in 3Q 2023). Revenue: ₹3.59b (flat on 3Q 2023). Net income: ₹123.1m (up 31% from 3Q 2023). Profit margin: 3.4% (up from 2.6% in 3Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings. Buy Or Sell Opportunity • Feb 06
Now 20% undervalued Over the last 90 days, the stock has risen 15% to ₹593. The fair value is estimated to be ₹745, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has declined by 9.8%. Revenue is forecast to grow by 23% in 2 years. Earnings are forecast to grow by 139% in the next 2 years. Valuation Update With 7 Day Price Move • Nov 24
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹609, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 27x in the Chemicals industry in India. Total returns to shareholders of 110% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹280 per share. Reported Earnings • Nov 03
Second quarter 2024 earnings released: EPS: ₹17.95 (vs ₹15.15 in 2Q 2023) Second quarter 2024 results: EPS: ₹17.95 (up from ₹15.15 in 2Q 2023). Revenue: ₹6.96b (up 20% from 2Q 2023). Net income: ₹531.5m (up 19% from 2Q 2023). Profit margin: 7.6% (down from 7.7% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.2% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings. 공시 • Aug 11
Insecticides (India) Limited, Annual General Meeting, Sep 23, 2023 Insecticides (India) Limited, Annual General Meeting, Sep 23, 2023, at 15:00 Indian Standard Time. Reported Earnings • Aug 11
First quarter 2024 earnings released: EPS: ₹9.85 (vs ₹12.94 in 1Q 2023) First quarter 2024 results: EPS: ₹9.85 (down from ₹12.94 in 1Q 2023). Revenue: ₹6.44b (up 15% from 1Q 2023). Net income: ₹291.4m (down 24% from 1Q 2023). Profit margin: 4.5% (down from 6.8% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Jun 01
Full year 2023 earnings released: EPS: ₹21.36 (vs ₹36.11 in FY 2022) Full year 2023 results: EPS: ₹21.36 (down from ₹36.11 in FY 2022). Revenue: ₹18.0b (up 20% from FY 2022). Net income: ₹632.1m (down 41% from FY 2022). Profit margin: 3.5% (down from 7.1% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth. Buying Opportunity • May 31
Now 23% undervalued Over the last 90 days, the stock is up 5.0%. The fair value is estimated to be ₹580, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.8% over the last 3 years. Earnings per share has grown by 12%. Revenue is forecast to grow by 26% in 2 years. Earnings is forecast to grow by 45% in the next 2 years. Price Target Changed • Mar 21
Price target decreased by 8.2% to ₹681 Down from ₹742, the current price target is an average from 3 analysts. New target price is 43% above last closing price of ₹477. Stock is up 14% over the past year. The company posted earnings per share of ₹36.11 last year. Valuation Update With 7 Day Price Move • Feb 24
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹470, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 63% over the past three years. Upcoming Dividend • Feb 17
Upcoming dividend of ₹3.00 per share at 0.5% yield Eligible shareholders must have bought the stock before 24 February 2023. Payment date: 15 March 2023. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (0.8%). 공시 • Feb 14
Insecticides (India) Limited Declares an Interim Dividend for Financial Year 2022-2023, Payable on February 24, 2023 Insecticides (India) Limited announced that at the board meeting held on February 13, 2023, the company declared an interim dividend of INR 3.00 per equity shares [30%] of face value of INR 10/- each for financial year 2022-2023. The record date as informed for the purpose of determining for entitlement of the shareholders for the payment of Interim Dividend is 24 day of February, 2023 and the Interim Dividend will be paid to the shareholders, subject to deduction/withholding of applicable taxes, within the time prescribed under law. Reported Earnings • Feb 14
Third quarter 2023 earnings released: EPS: ₹3.16 (vs ₹2.79 in 3Q 2022) Third quarter 2023 results: EPS: ₹3.16 (up from ₹2.79 in 3Q 2022). Revenue: ₹3.57b (up 14% from 3Q 2022). Net income: ₹93.7m (up 14% from 3Q 2022). Profit margin: 2.6% (in line with 3Q 2022). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth. Price Target Changed • Jan 06
Price target increased to ₹742 Up from ₹676, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of ₹727. Stock is up 52% over the past year. The company posted earnings per share of ₹36.11 last year. Reported Earnings • Nov 09
Second quarter 2023 earnings released: EPS: ₹15.15 (vs ₹14.15 in 2Q 2022) Second quarter 2023 results: EPS: ₹15.15 (up from ₹14.15 in 2Q 2022). Net income: ₹448.3m (up 7.1% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Sep 08
Upcoming dividend of ₹3.00 per share Eligible shareholders must have bought the stock before 15 September 2022. Payment date: 23 October 2022. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (0.7%). Price Target Changed • Aug 18
Price target increased to ₹925 Up from ₹807, the current price target is provided by 1 analyst. New target price is 9.2% below last closing price of ₹1,019. Stock is up 35% over the past year. The company posted earnings per share of ₹54.17 last year. Reported Earnings • Aug 14
First quarter 2023 earnings released: EPS: ₹19.41 (vs ₹17.37 in 1Q 2022) First quarter 2023 results: EPS: ₹19.41 (up from ₹17.37 in 1Q 2022). Revenue: ₹5.61b (up 20% from 1Q 2022). Net income: ₹383.1m (up 9.6% from 1Q 2022). Profit margin: 6.8% (down from 7.5% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings. Price Target Changed • Jun 02
Price target increased to ₹803 Up from ₹748, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of ₹788. Stock is up 43% over the past year. The company posted earnings per share of ₹54.17 last year. Reported Earnings • May 27
Full year 2022 earnings released: EPS: ₹54.17 (vs ₹45.43 in FY 2021) Full year 2022 results: EPS: ₹54.17 (up from ₹45.43 in FY 2021). Revenue: ₹15.1b (up 6.2% from FY 2021). Net income: ₹1.07b (up 14% from FY 2021). Profit margin: 7.1% (up from 6.6% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Board Change • Apr 27
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 1 experienced director. 5 highly experienced directors. Independent Non-Executive Women Director Praveen Gupta was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 13
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹4.18 (up from ₹2.97 in 3Q 2021). Revenue: ₹3.14b (up 4.9% from 3Q 2021). Net income: ₹82.6m (up 34% from 3Q 2021). Profit margin: 2.6% (up from 2.1% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Reported Earnings • Nov 13
Second quarter 2022 earnings released: EPS ₹21.22 (vs ₹20.13 in 2Q 2021) The company reported a mediocre second quarter result with weaker revenues, although earnings were flat and profit margins improved. Second quarter 2022 results: Revenue: ₹4.44b (down 2.7% from 2Q 2021). Net income: ₹418.8m (flat on 2Q 2021). Profit margin: 9.4% (up from 9.1% in 2Q 2021). The increase in margin was driven by lower expenses. Reported Earnings • Aug 11
First quarter 2022 earnings released: EPS ₹17.37 (vs ₹11.79 in 1Q 2021) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹4.68b (up 14% from 1Q 2021). Net income: ₹349.6m (up 44% from 1Q 2021). Profit margin: 7.5% (up from 5.9% in 1Q 2021). The increase in margin was driven by higher revenue. Reported Earnings • Jun 20
Full year 2021 earnings released: EPS ₹45.43 (vs ₹42.05 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹14.3b (up 4.7% from FY 2020). Net income: ₹939.0m (up 8.0% from FY 2020). Profit margin: 6.6% (up from 6.4% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Jun 11
Investor sentiment improved over the past week After last week's 16% share price gain to ₹639, the stock trades at a trailing P/E ratio of 20.4x. Average trailing P/E is 21x in the Chemicals industry in India. Total loss to shareholders of 9.1% over the past three years. Price Target Changed • Apr 10
Price target decreased to ₹529 Down from ₹574, the current price target is provided by 1 analyst. New target price is 13% above last closing price of ₹468. Stock is up 35% over the past year. Is New 90 Day High Low • Mar 15
New 90-day low: ₹446 The company is down 5.0% from a price of ₹470 on 15 December 2020. Underperformed the Indian market, which is up 14% over the last 90 days. Lagged the Chemicals industry, which is up 9.0% over the same period. Reported Earnings • Feb 06
Third quarter 2021 earnings released: EPS ₹2.97 (vs ₹4.30 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ₹3.00b (up 14% from 3Q 2020). Net income: ₹61.5m (down 31% from 3Q 2020). Profit margin: 2.0% (down from 3.4% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 15% per year whereas the company’s share price has fallen by 17% per year. Is New 90 Day High Low • Feb 04
New 90-day high: ₹511 The company is up 11% from its price of ₹460 on 06 November 2020. The Indian market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 14% over the same period. Is New 90 Day High Low • Jan 15
New 90-day high: ₹510 The company is up 7.0% from its price of ₹478 on 16 October 2020. The Indian market is up 26% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 24% over the same period. Reported Earnings • Nov 11
Second quarter 2021 earnings released: EPS ₹20.13 The company reported a poor second quarter result with weaker earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: ₹4.61b (down 8.4% from 2Q 2020). Net income: ₹416.1m (down 15% from 2Q 2020). Profit margin: 9.0% (in line with 2Q 2020). Is New 90 Day High Low • Nov 10
New 90-day low: ₹445 The company is down 6.0% from its price of ₹475 on 12 August 2020. The Indian market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period. 
